These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24138664)

  • 1. New pharmacologic treatments for familial hypercholesterolemia.
    McDonough A; Matura LA; Carroll D
    Nurs Womens Health; 2013 Oct; 17(5):443-7. PubMed ID: 24138664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
    Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
    J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of lomitapide on cardiovascular outcome measures in homozygous familial hypercholesterolemia: A modelling analysis.
    Leipold R; Raal F; Ishak J; Hovingh K; Phillips H
    Eur J Prev Cardiol; 2017 Nov; 24(17):1843-1850. PubMed ID: 28925748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.
    Marbach JA; McKeon JL; Ross JL; Duffy D
    Pharmacotherapy; 2014 Sep; 34(9):961-72. PubMed ID: 24899514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two new drugs for homozygous familial hyperchelesterolemia.
    Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581
    [No Abstract]   [Full Text] [Related]  

  • 8. Lomitapide for the management of homozygous familial hypercholesterolemia.
    deGoma EM
    Rev Cardiovasc Med; 2014; 15(2):109-18. PubMed ID: 25051128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis.
    Blom DJ; Raal FJ; Santos RD; Marais AD
    Curr Atheroscler Rep; 2019 Nov; 21(12):48. PubMed ID: 31741187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.
    Won JI; Zhang J; Tecson KM; McCullough PA
    Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia.
    Blom DJ; Cuchel M; Ager M; Phillips H
    Orphanet J Rare Dis; 2018 Jun; 13(1):96. PubMed ID: 29925433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia.
    Khoury E; Brisson D; Roy N; Tremblay G; Gaudet D
    Expert Opin Drug Saf; 2019 May; 18(5):403-414. PubMed ID: 30945578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mipomersen sodium (Kynamro).
    Hovingh K; Besseling J; Kastelein J
    Expert Opin Drug Saf; 2013 Jul; 12(4):569-79. PubMed ID: 23611600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia.
    Raal FJ; Braamskamp MJ; Selvey SL; Sensinger CH; Kastelein JJ
    J Clin Lipidol; 2016; 10(4):860-869. PubMed ID: 27578117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice.
    Marbach JA; Thapa J; Goldenberg E; Duffy D
    Del Med J; 2015 Aug; 87(8):238-43. PubMed ID: 26402926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.
    Santos RD; Raal FJ; Catapano AL; Witztum JL; Steinhagen-Thiessen E; Tsimikas S
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):689-99. PubMed ID: 25614280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
    Perry CM
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two new drugs for homozygous familial hypercholesterolemia: managing benefits and risks in a rare disorder.
    Smith RJ; Hiatt WR
    JAMA Intern Med; 2013 Sep; 173(16):1491-2. PubMed ID: 23649296
    [No Abstract]   [Full Text] [Related]  

  • 19. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
    Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is mipomersen ready for clinical implementation? A transatlantic dilemma.
    Sjouke B; Balak DM; Beuers U; Ratziu V; Stroes ES
    Curr Opin Lipidol; 2013 Aug; 24(4):301-6. PubMed ID: 23759796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.